[F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels

Background: Prostate cancer (PCa) patients with biochemical recurrence (BCR) following radical prostatectomy or radiation therapy often present with very low prostate-specific antigen (PSA) levels (⩽0.5 ng/mL). Accurate detection of recurrence at such low levels is crucial for guiding treatment deci...

Full description

Bibliographic Details
Published in:	Biomarker Insights
Main Authors:	Ko-Han Lin, Tzu-Chun Wei, Shu-Huei Shen, William Ji-Shien Huang, Mei-Hua Chuang, Nan-Jing Peng, Wen-Tao Huang, Yuh-Feng Wang
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-03-01
Online Access:	https://doi.org/10.1177/11772719251324307

Similar Items

The value of 18F-PSMA-1007 PET/CT in preoperative evaluation of prostate cancer within PSA gray area
by: Shuying Bian, et al.
Published: (2024-08-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
by: Rie von Eyben, et al.
Published: (2023-08-01)

Intrahepatic cholangiocarcinoma detected on 18F-PSMA-1007 PET/MR imaging in a prostate cancer patient: a case report and literature review
by: Yu Sun, et al.
Published: (2024-06-01)

Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI
by: Yan-Nan Zhang, et al.
Published: (2022-07-01)

Diagnostic value of 18F-PSMA-1007 PET/CT for predicting the pathological grade of prostate cancer
by: Xiao-Bo Niu, et al.
Published: (2024-12-01)

Skeletal F-PSMA-1007 uptake in prostate cancer patients
by: Jorinde Janssen, et al.
Published: (2023-06-01)

Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
by: Wenxiao Yu, et al.
Published: (2023-08-01)

Supraclavicular nodal metastasis at primary staging of prostate cancer using 18F-PSMA-1007 PET/CT
by: Samuel Nguku Gitau, et al.
Published: (2025-03-01)

Predictive value of volumetric parameters based on 18F-PSMA-1007 PET/CT for prostate cancer metastasis
by: Yanmei Li, et al.
Published: (2024-02-01)

An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
by: Jun Dang, et al.
Published: (2023-08-01)

The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
by: Jun-jie Hong, et al.
Published: (2020-11-01)

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging
by: Venkata Avinash Chikatamarla, et al.
Published: (2021-12-01)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
by: Peter Iversen, et al.
Published: (2022-01-01)

Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer
by: Negar Abdi, et al.
Published: (2025-03-01)

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
by: André H. Dias, et al.
Published: (2023-04-01)

Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer
by: Yuping Zeng, et al.
Published: (2022-06-01)

The value of habitat analysis based on 18F-PSMA-1007 PET/CT images for prostate cancer risk grading
by: Yang Wang, et al.
Published: (2025-07-01)

Isolated Rectal Metastases from Locally Advanced Carcinoma Prostate Detected by 18F-PSMA-1007 PET/CT
by: Shashank Shekhar Singh, et al.
Published: (2022-09-01)

A comparative study of 18F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer
by: Zhenyan Ye, et al.
Published: (2024-07-01)

Evaluating the value of 18F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard
by: Liang Luo, et al.
Published: (2023-11-01)

Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
by: Lena M. Mittlmeier, et al.
Published: (2021-05-01)

A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence
by: Nathan Poterszman, et al.
Published: (2024-05-01)

[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 Imaging
by: Moritz B. Bastian, et al.
Published: (2024-10-01)

Multimodal integration of [18F]PSMA-1007 PET/CT semiquantitative parameters and clinicopathological data for predicting prostate cancer metastasis
by: JiaYing Yang, et al.
Published: (2025-10-01)

The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer
by: J. Antonio Serna-Macias, et al.
Published: (2024-10-01)

Biphasic contrast-enhanced [18F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer
by: Eduards Mamlins, et al.
Published: (2025-05-01)

Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01)

Correction: a comparative study of 18 F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer
by: Zhenyan Ye, et al.
Published: (2024-09-01)

18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer
by: Siying Dong, et al.
Published: (2022-12-01)

(18F)-PSMA-1007PET/CT in patients with biochemical recurrence after radical prostatectomy: Diagnostic performance and impact on treatment management
by: Jia Jiang, et al.
Published: (2023-03-01)

Agreement between PSMA-RADS and E-PSMA systems in classifying [18F]PSMA-1007 PET/CT lesions among prostate cancer patients: exploring the correlation between lesion size and uptake
by: Miguel Mendoza-Ávila, et al.
Published: (2024-03-01)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
by: Oscar Lilleby, et al.
Published: (2019-11-01)

Recurrent Prostate Cancer Diagnostics with <sup>18</sup>F-PSMA-1007 PET/CT: A Systematic Review of the Current State
by: Laura Saule, et al.
Published: (2022-12-01)

A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
by: Ian Alberts, et al.
Published: (2022-01-01)

A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
by: Ian Alberts, et al.
Published: (2022-01-01)

The value of  18 F-PSMA-1007 PET/CT in the early diagnosis and clinical treatment of patients with biochemical recurrence after radical prostatectomy
by: LI Zeng , WU Yi , CHEN Zhuzhong , CHEN Li , LIAO Hong , MAO Dun , XIAO Yingming , XIE Hongping , LI Xiuli , YANG Shengke , ZHOU Shukui , ZHONG Lei , LU Hao , CHEN Yongji
Published: (2021-11-01)

Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis
by: Xue Liu, et al.
Published: (2022-07-01)

AI based automatic measurement of split renal function in [18F]PSMA-1007 PET/CT
by: Kristian Valind, et al.
Published: (2025-06-01)

A fully automated AI-based method for tumour detection and quantification on [18F]PSMA-1007 PET–CT images in prostate cancer
by: Elin Trägårdh, et al.
Published: (2025-08-01)